In summary, the present study showed that East Asian NSCLC patients harboring EGFR L858R mutations were associated with an inflammatory tumor microenvironment, which may result in superior patient response to PD-1 inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.